South Korea
· Delayed Price · Currency is KRW Genesystem Statistics
Total Valuation
Genesystem has a market cap or net worth of KRW 60.76 billion. The enterprise value is 48.13 billion.
| Market Cap | 60.76B |
| Enterprise Value | 48.13B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Genesystem has 7.03 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 7.03M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 18.39% |
| Owned by Institutions (%) | 18.39% |
| Float | 5.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 38.27 |
| PB Ratio | 2.09 |
| P/TBV Ratio | 2.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.27 |
| EV / Sales | 30.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.39 |
Financial Position
The company has a current ratio of 10.40, with a Debt / Equity ratio of 0.14.
| Current Ratio | 10.40 |
| Quick Ratio | 8.22 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.54 |
| Interest Coverage | -72.89 |
Financial Efficiency
Return on equity (ROE) is -32.70% and return on invested capital (ROIC) is -14.67%.
| Return on Equity (ROE) | -32.70% |
| Return on Assets (ROA) | -13.92% |
| Return on Capital (ROIC) | -14.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0.76 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.88% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +4.88% |
| 50-Day Moving Average | 9,862.60 |
| 200-Day Moving Average | 8,589.55 |
| Relative Strength Index (RSI) | 37.65 |
| Average Volume (20 Days) | 39,272 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genesystem had revenue of KRW 1.57 billion and -11.27 billion in losses. Loss per share was -1,623.49.
| Revenue | 1.57B |
| Gross Profit | -904.72M |
| Operating Income | -9.05B |
| Pretax Income | -9.31B |
| Net Income | -11.27B |
| EBITDA | -8.64B |
| EBIT | -9.05B |
| Loss Per Share | -1,623.49 |
Balance Sheet
The company has 16.73 billion in cash and 4.09 billion in debt, giving a net cash position of 12.63 billion or 1,796.48 per share.
| Cash & Cash Equivalents | 16.73B |
| Total Debt | 4.09B |
| Net Cash | 12.63B |
| Net Cash Per Share | 1,796.48 |
| Equity (Book Value) | 28.78B |
| Book Value Per Share | 4,133.79 |
| Working Capital | 19.38B |
Cash Flow
In the last 12 months, operating cash flow was -7.36 billion and capital expenditures -166.72 million, giving a free cash flow of -7.53 billion.
| Operating Cash Flow | -7.36B |
| Capital Expenditures | -166.72M |
| Free Cash Flow | -7.53B |
| FCF Per Share | -1,070.92 |
Margins
| Gross Margin | -57.76% |
| Operating Margin | -577.83% |
| Pretax Margin | -594.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genesystem does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.05% |
| Shareholder Yield | -1.05% |
| Earnings Yield | -18.79% |
| FCF Yield | -12.39% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genesystem has an Altman Z-Score of 9.98.
| Altman Z-Score | 9.98 |
| Piotroski F-Score | n/a |